RT Journal Article
SR Electronic
T1 A Phase 2/3 study of S-217622 in participants with SARS-CoV-2 infection (Phase 3 part)
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.07.15.22277670
DO 10.1101/2022.07.15.22277670
A1 Yotsuyanagi, Hiroshi
A1 Ohmagari, Norio
A1 Doi, Yohei
A1 Imamura, Takumi
A1 Sonoyama, Takuhiro
A1 Ichihashi, Genki
A1 Sanaki, Takao
A1 Tsuge, Yuko
A1 Uehara, Takeki
A1 Mukae, Hiroshi
YR 2023
UL http://medrxiv.org/content/early/2023/01/12/2022.07.15.22277670.abstract
AB Background Limited treatment options exist for patients with mild-to-moderate coronavirus disease 2019 (COVID-19), irrespective of vaccination history or risk status. Ensitrelvir is a novel oral severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 3C-like protease inhibitor. While phase 2 studies of ensitrelvir have demonstrated promising results in treating mild-to-moderate COVID-19, evaluation of its clinical efficacy due to shifting vaccination status and emergence of the Omicron variant represents significant challenges. Here, we describe the protocol for a phase 3 study designed to evaluate the efficacy and safety of ensitrelvir in patients with mild-to-moderate COVID-19, regardless of risk status or vaccination history.Methods This is a multicenter, randomized, double-blind, placebo-controlled, phase 3 study. Patients with mild-to-moderate COVID-19 within 120 hours from onset will be randomized in a 1:1:1 ratio into 3 treatment arms–ensitrelvir 125 mg (375 mg loading dose on Day 1), ensitrelvir 250 mg (750 mg loading dose on Day 1), and placebo. The study interventions will be administered orally, once daily, for 5 days. The primary endpoint will be the time to resolution of 5 symptoms of COVID-19 (stuffy or runny nose, sore throat, cough, feeling hot or feverish, and low energy or tiredness), and the key secondary endpoints will include the change from baseline on Day 4 in the amount of SARS-CoV-2 viral RNA and the time to first negative SARS-CoV-2 viral titer. The primary population for the primary and key secondary endpoints will be patients with <72 hours from COVID-19 onset to randomization and, subsequently, patients in entire patient population (<120 hours) in the ensitrelvir 125 mg group. Closed testing procedure will be used for the primary and key secondary endpoints in both the primary and entire patient populations. All safety assessments and adverse events will be reported.Discussion In a post hoc analysis of the phase 2b study, compared with placebo, ensitrelvir demonstrated a reduced time to resolution of 5 symptoms in patients with mild-to-moderate COVID-19. Through this study, we intend to validate and establish the efficacy and safety of ensitrelvir in patients with mild-to-moderate COVID-19.Trial registration Japan Registry of Clinical Trials (https://jrct.niph.go.jp): jRCT2031210350.Competing Interest StatementHY reports consulting fees from Shionogi, lecture fees from Shionogi and ViiV Healthcare, and travel support from Shionogi outside the submitted work. He serves as an advisory board member for Shionogi and President of the Japanese Society of Infectious Diseases. NO declares no conflict of interest. YD reports grants from Shionogi and Entasis; consulting fees from Shionogi, Meiji Seika Pharma, Gilead Sciences, GSK, MSD, Chugai, and bioMerieux; and lecture fees from MSD, AstraZeneca, Shionogi, and Teijin Healthcare outside the submitted work and serves as an advisory board member for FujiFilm. TI, T Sonoyama, GI, T Sanaki, YT, and TU are full-time employees of Shionogi & Co., Ltd., and may own stocks or stock options. HM has received funding relevant to the submitted work from Shionogi and grants from Taisho Pharma; lecture fees from Pfizer, MSD, Shionogi, and Taisho Pharma; and advisory fees from Pfizer, MSD, and Shionogi outside the submitted work.Clinical TrialJapan Registry of Clinical Trials (https://jrct.niph.go.jp): jRCT2031210350.Funding StatementThis study was funded by Shionogi & Co., Ltd., and financially supported by the Organization of the Ministry of Health, Labor and Welfare. Employees of Shionogi & Co., Ltd., participated in and approved the design and conduct of the study, wrote the protocol, and were involved in the collection, management, analysis, and interpretation of data. Institutional authors reviewed and approved the protocol and collected and interpreted the data.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The study was reviewed and approved by the institutional review boards of all participating institutions (the final list will be provided together with another manuscript once the study is completed). I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors3CL3C-likeAEadverse eventANCOVAanalysis of covarianceCIconfidence intervalCIOMSCouncil for International Organizations of Medical SciencesCOVID-19coronavirus disease 2019CYP3Acytochrome P450 3AFDA = Food and Drug AdministrationeCRFelectronic case report formICHInternational Council for Harmonization of Technical Requirements for Pharmaceuticals for Human UseITTintention-to-treatmITTmodified intention-to-treatRNAribonucleic acidRT-PCRreverse transcription-polymerase chain reactionSAEserious adverse eventSAPsafety analysis populationSARS-CoV-2severe acute respiratory syndrome coronavirus 2SpO2saturation of percutaneous oxygenVOCvariant of concernWHOWorld Health Organization